ArticleJournal of hepatocellular carcinoma2026
Predictive Modeling and Mendelian Randomization for Identifying HCC Patients with High Response to TACE with Atezolizumab and Bevacizumab.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hepatocellular carcinoma (HCC) is a major cause of cancer deaths. This study developed a clinical prediction model to identify patients likely to respond to transcatheter arterial chemoembolization (TACE) combined with atezolizumab and bevacizumab (Atez/Bev), using Mendelian randomization (MR) to validate the therapeutic effect on HCC via Patients and Methods: A retrospective analysis of 258 unresectable HCC patients administered TACE, with or without Atez/Bev therapy, was conducted. Propensity score matching (PSM) was employed to compare objective response rates (ORRs). A predictive model for response to TACE+Atez/Bev was developed using logistic regression and validated. MR was used to analyze the causal relationships between the Results: After PSM, the TACE+Atez/Bev group demonstrated significantly higher ORR compared with the TACE group (73.8% vs 56.3%, Conclusion: We developed a predictive model for TACE+Atez/Bev therapy, enabling effective patient screening. MR validated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.